208 related articles for article (PubMed ID: 10449126)
1. Prognostic factors of Guillain-Barré syndrome after intravenous immunoglobulin or plasma exchange. Dutch Guillain-Barré Study Group.
Visser LH; Schmitz PI; Meulstee J; van Doorn PA; van der Meché FG
Neurology; 1999 Aug; 53(3):598-604. PubMed ID: 10449126
[TBL] [Abstract][Full Text] [Related]
2. Treatment related fluctuations in Guillain-Barré syndrome after high-dose immunoglobulins or plasma-exchange.
Kleyweg RP; van der Meché FG
J Neurol Neurosurg Psychiatry; 1991 Nov; 54(11):957-60. PubMed ID: 1800666
[TBL] [Abstract][Full Text] [Related]
3. Plasma exchange versus intravenous immunoglobulin for Guillain-Barré syndrome.
Hughes RA
Ther Apher; 1997 May; 1(2):129-30. PubMed ID: 10225757
[TBL] [Abstract][Full Text] [Related]
4. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group.
Lancet; 1997 Jan; 349(9047):225-30. PubMed ID: 9014908
[TBL] [Abstract][Full Text] [Related]
5. Cytomegalovirus infection and Guillain-Barré syndrome: the clinical, electrophysiologic, and prognostic features. Dutch Guillain-Barré Study Group.
Visser LH; van der Meché FG; Meulstee J; Rothbarth PP; Jacobs BC; Schmitz PI; van Doorn PA
Neurology; 1996 Sep; 47(3):668-73. PubMed ID: 8797462
[TBL] [Abstract][Full Text] [Related]
6. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group.
van der Meché FG; Schmitz PI
N Engl J Med; 1992 Apr; 326(17):1123-9. PubMed ID: 1552913
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for treatment related clinical fluctuations in Guillain-Barré syndrome. Dutch Guillain-Barré study group.
Visser LH; van der Meché FG; Meulstee J; van Doorn PA
J Neurol Neurosurg Psychiatry; 1998 Feb; 64(2):242-4. PubMed ID: 9489539
[TBL] [Abstract][Full Text] [Related]
8. The Italian Guillain-Barré Study Group. The prognosis and main prognostic indicators of Guillain-Barré syndrome: a multicentre prospective study of 297 patients.
Hughes RA; Hadden RD; Rees JH; Swan AV
Brain; 1998 Apr; 121 ( Pt 4)():767-9. PubMed ID: 9577400
[No Abstract] [Full Text] [Related]
9. [Treatment of Guillain-Barré syndrome with high-dose intravenous immunoglobulins--a comparison with plasma exchange].
Kamei T; Nakagawa H; Uchiyama F; Fukuyama J
Rinsho Shinkeigaku; 1993 Jun; 33(6):660-2. PubMed ID: 8403689
[TBL] [Abstract][Full Text] [Related]
10. [Treatments and outcome predictors in Guillain-Barré syndrome].
Uchibori A; Chiba A
Nihon Rinsho; 2013 May; 71(5):845-9. PubMed ID: 23777092
[TBL] [Abstract][Full Text] [Related]
11. [A case of Guillain-Barré syndrome treated with plasma exchange and intravenous high-dose immune globulin].
Imai N; Miyata K; Terayama Y; Ishihara N
Rinsho Shinkeigaku; 1997 Jun; 37(6):520-2. PubMed ID: 9366182
[TBL] [Abstract][Full Text] [Related]
12. Intravenous immunoglobulin for Guillain-Barré syndrome.
Hughes RA; Raphaël JC; Swan AV; van Doorn PA
Cochrane Database Syst Rev; 2001; (2):CD002063. PubMed ID: 11406030
[TBL] [Abstract][Full Text] [Related]
13. Guillain-Barré syndrome without sensory loss (acute motor neuropathy). A subgroup with specific clinical, electrodiagnostic and laboratory features. Dutch Guillain-Barré Study Group.
Visser LH; Van der Meché FG; Van Doorn PA; Meulstee J; Jacobs BC; Oomes PG; Kleyweg RP; Meulstee J
Brain; 1995 Aug; 118 ( Pt 4)():841-7. PubMed ID: 7655882
[TBL] [Abstract][Full Text] [Related]
14. [Immunoglobulins or plasma exchange? Guillain-Barré syndrome: indications for plasma exchange and immunoglobulins].
Raphaël JC; Chevret S; Jars-Guincestre MC; Chastang C; Gajdos P
Ann Med Interne (Paris); 1993; 144(8):526-31. PubMed ID: 8179242
[TBL] [Abstract][Full Text] [Related]
15. Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barré syndrome.
Bril V; Ilse WK; Pearce R; Dhanani A; Sutton D; Kong K
Neurology; 1996 Jan; 46(1):100-3. PubMed ID: 8559353
[TBL] [Abstract][Full Text] [Related]
16. High dose intravenous immune globulins and plasma exchange in Guillain-Barré Syndrome.
Ravasio A; Pasquinelli M; Currò Dossi B; Neri W; Guidi C; Gessaroli M; Rasi F; Fabbri R; Mazzini G; Rebucci GG
Ital J Neurol Sci; 1995 Oct; 16(7):487-92. PubMed ID: 8749707
[TBL] [Abstract][Full Text] [Related]
17. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group.
Hadden RD; Cornblath DR; Hughes RA; Zielasek J; Hartung HP; Toyka KV; Swan AV
Ann Neurol; 1998 Nov; 44(5):780-8. PubMed ID: 9818934
[TBL] [Abstract][Full Text] [Related]
18. Relapses in the Guillain-Barré syndrome after treatment with intravenous immune globulin or plasma exchange.
Romano JG; Rotta FT; Potter P; Rosenfeld V; Santibanez R; Rocha B; Bradley WG
Muscle Nerve; 1998 Oct; 21(10):1327-30. PubMed ID: 9736064
[TBL] [Abstract][Full Text] [Related]
19. The Guillain-Barré syndrome: plasma exchange or immunoglobulins intravenously?
van der Meché FG
Ann Med Interne (Paris); 1994; 145(5):293-5. PubMed ID: 7985934
[No Abstract] [Full Text] [Related]
20. Intravenous immunoglobulin for Guillain-Barré syndrome.
Hughes RA; Raphaël JC; Swan AV; Doorn PA
Cochrane Database Syst Rev; 2004; (1):CD002063. PubMed ID: 14973982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
